Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest

European Journal of Cancer

Volumn 73, Issue , 2017, Pages 74-84

  Cremolini, Chiara ^a,b   Casagrande, Mariaelena ^c   Loupakis, Fotios ^d   Aprile, Giuseppe ^c   Bergamo, Francesca ^d   Masi, Gianluca ^a,b   Moretto R, Roberto ^a,b   Pietrantonio, Filippo ^e   Marmorino, Federica ^a,b   Zucchelli, Gemma ^a,b   Tomasello, Gianluca ^f   Tonini, Giuseppe ^g   Allegrini, Giacomo ^h   Granetto, Cristina ⁱ   Ferrari, Laura ^c   Urbani, Lucio ^a   Cillo, Umberto ^d   Pilati, Pierluigi ^j   Sensi, Elisa ^e   Pellegrinelli, Alessio ^b   Milione, Massimo ^b   Fontanini, Gabriella ^e   Falcone, Alfredo ^a,b   more..

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f CREMONA HOSPITAL   (Italy)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^h Felice Lotti Hospital   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j S ANTONIO HOSPITAL   (Italy)

more..

Author keywords

Bevacizumab; FOLFOXIRI; Liver metastases; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OUTCOME; CODON; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TUMOR VOLUME; AGED; ANALOGS AND DERIVATIVES; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; SECONDARY; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85007560352     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.028     Document Type: Article

References (26)

1. [1] Tomlinson, J.S., Jarnagin, W.R., DeMatteo, R.P., Fong, Y., Kornprat, P., Gonen, M., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25 (2007), 4575–4580.
2. [2] Adam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41 (2015), 729–741.
3. [3] Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007), 1670–1676.
4. [4] Masi, G., Loupakis, F., Pollina, L., Vasile, E., Cupini, S., Ricci, S., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249 (2009), 420–425.
5. [5] Masi, G., Vasile, E., Loupakis, F., Cupini, S., Fornaro, L., Baldi, G., et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 103 (2011), 21–30.
6. [6] Cremolini, C., Loupakis, F., Antoniotti, C., Lonardi, S., Masi, G., Salvatore, L., et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26 (2015), 1188–1194.
7. [7] Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16 (2015), 1306–1315.
8. [8] Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371 (2014), 1609–1618.
9. [9] Gruenberger, T., Bridgewater, J., Chau, I., Garcia-Alfonso, P., Rivoire, M., Mudan, S., et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26 (2015), 702–708.
10. [10] Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11 (2010), 845–852.
11. [11] Salvatore, L., Loupakis, F., Cremolini, C., Masi, G., Bergamo, F., Galiano, A., et al. Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): the MOMA trial. J Clin Oncol(Suppl. 32), 2014, 5s abstr TPS3664.
12. [12] Alberts, S., Poston, G., OncoSurge: a strategy for long-term survival in metastatic colorectal cancer. Colorectal Dis 5:Suppl. 3 (2003), 20–28.
13. [13] Arcila, M., Lau, C., Nafa, K., Ladanyi, M., Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 13 (2011), 64–73.
14. [14] Fumagalli, D., Gavin, P.G., Taniyama, Y., Kim, S.I., Choi, H.J., Park, S., et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer, 10, 2010, 101.
15. [15] Nordlinger, B., Guiguet, M., Vaillant, J.C., Balladur, P., Boudjema, K., Bachellier, P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77 (1996), 1254–1262.
16. [16] Fong, Y., Fortner, J., Sun, R.L., Brennan, M.F., Blumgart, L.H., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999), 309–318 discussion 318–321.
17. [17] Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:8 (2016), 1386–1422.
18. [18] Folprecht, G., Gruenberger, T., Bechstein, W.O., Raab, H.R., Lordick, F., Hartmann, J.T., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
19. [19] Neumann U, Denecke T, Pratschke J, Lang H, Bemelmans M, Becker T, et al. Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) – a retrospective, central evaluation of FIRE-3. Proceedings of ESMO 2016, Ann Oncol 2016:27(Suppl. 6).
20. [20] Ye, L.C., Liu, T.S., Ren, L., Wei, Y., Zhu, D.X., Zai, S.Y., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31 (2013), 1931–1938.
21. [21] Douillard, J.Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J.H., Tabernero, J., Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 51 (2015), 1231–1242.
22. [22] Kohne, C.H., Bokemeyer, C., Folprecht, G., Sartorius, U., Schlichting, M., Rougier, P.R., et al. Chemotherapy plus cetuximab in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: a pooled analysis of the CRYSTAL and OPUS studies. J Clin Oncol(Suppl. 30), 2012 abstr 3562.
23. [23] Cremolini, C., Loupakis, F., Masi, G., Lonardi, S., Granetto, C., Mancini, M.L., et al. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol 27 (2016), 843–849.
24. [24] Ychou, M., Rivoire, M., Thezenas, S., Quenet, F., Delpero, J.R., Rebischung, C., et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: a phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial. J Clin Oncol(Suppl. 34), 2016 abstr 3512.
25. [25] Schirripa, M., Bergamo, F., Cremolini, C., Casagrande, M., Lonardi, S., Aprile, G., et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 112 (2015), 1921–1928.
26. [26] Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50 (2014), 57–63.